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Summary
The neuropeptide relaxin-3 and its cognate G-protein-coupled receptor, RXFP3, have been implicat-
ed in the control of feeding behaviour in rats. For example, relaxin-3-positive projections and RXFP3 
are present within hypothalamic feeding circuits, and icv injection of human relaxin-3 (~0.2 to 1.0 
nmol) robustly increases feeding behaviour in satiated rats. To explore whether this action is con-
served in other experimental species, the present study examined feeding behaviour in C57BL/6J 
mice following RXFP3 modulation, as mice display near identical regional distribution patterns of 
relaxin-3/RXFP3, and relaxin-3/RXFP3 signalling has been shown to modulate behavioural arousal 
in both species. Central injection of the RXFP3 agonists R3/I5 or H3 relaxin (0.5 nmol, icv) did not 
alter chow consumption in satiated mice relative to vehicle controls, during the 60 min after treat-
ment. Furthermore, relaxin-3 knockout mice displayed similar basal 24-h chow consumption and 
1-h palatable food consumption to wildtype littermate controls; although further studies involving 
acute pharmacological antagonism of RXFP3 in WT mice are required to eliminate the likelihood of 
compensation in these life-long relaxin-3 deficient mice. Taken together, these findings are in con-
trast to the potent orexigenic effects of RXFP3 activation observed in rats, and may reflect differen-
tial RXFP3 expression within hypothalamic neuron populations in the rat and mouse, or differences 
in signalling upstream or downstream of relaxin-3/RXFP3 networks in these two species.
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Introduction
The neuropeptide relaxin-3 is produced by neurons in the nucleus incertus, which 
send relaxin-3-positive projections to a broad range of brain regions that express the 
cognate receptor for relaxin-3, RXFP3 (Ma et al., 2007; Smith et al., 2010, 2011). The 
discovery of a high density of RXFP3 within hypothalamic regions associated with 
the control of feeding prompted several studies in the rat, which demonstrated that 
intracerebroventricular (icv) infusion of relaxin-3 or specific RXFP3 agonists robust-
ly increase feeding behaviour at doses ranging from 180-1000 pmol (McGowan et al., 
2005; Ganella et al., 2012). However, as it has not yet been reported whether or not 
these orexigenic effects are conserved in other experimental species, the present study 
assessed feeding behaviour in C57BL/6J mice following modulation of RXFP3.
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Methods
Icv infusion studies: Adult male C57BL/6J mice were anaesthetised and surgically 
implanted with an indwelling guide cannula targeting the lateral cerebral ventricle. 
After recovery, the location of the guide cannula was verified by testing for a drink-
ing response after injection of angiotensin II (25 ng). Satiated mice with ad libitum 
access to food were injected during the light phase with either artificial cerebrospinal 
fluid (aCSF) vehicle (1 µl), or 500 pmol of the RXFP3 agonists R3/I5 or H3 relaxin (Liu 
et al., 2005). The amount of food consumed in their home-cage over the subsequent 
60 min was then assessed. Relaxin-3 KO mouse studies: The amount of regular chow 
consumed by backcrossed adult male C57BL/6J relaxin-3 knockout (KO) and wild-
type (WT) littermate mice (Smith et al., 2012) was measured daily over 4 weeks and 
averaged. To assess palatable food consumption, satiated adult, male relaxin-3 KO 
and WT littermate mice were provided with a pellet of palatable food (consisting of 
approximately equal parts fat, protein and sugar) in their home cage for 1 h during 
the light phase. Due to the variable and generally low amounts consumed during the 
first exposure, the experiment was repeated on 3 consecutive weeks, and data from 
the 3rd week was assessed. Statistical analysis: Feeding data were analysed by one-way 
RM ANOVA or unpaired t-tests, as appropriate.
Results
Icv infusion of RXFP3 agonists did not increase feeding in mice: In contrast to obser-
vations in rats under similar conditions, icv infusion of 500 pmol R3/I5 or H3 relaxin 
in satiated mice during the light phase did not alter food consumption, compared to 
vehicle controls (Fig. 1A). This lack of effect was not due to a lack of biological activ-
ity of the R3/I5 or H3 relaxin samples, as these batches of peptide were observed to 
increase feeding in rats at the same bolus dose in studies in our laboratory (Shaban-
poor et al., 2012), despite the relatively larger brain size and cerebrospinal fluid vol-
ume in this species.
Life-long relaxin-3 deficiency did not alter feeding behaviour in mice: In line with previ-
ous observations that backcrossed C57BL/6J relaxin-3 KO mice display normal body-
weights (Smith et al., 2012), no differences between relaxin-3 KO and WT littermates 
were observed in measures of average 24-h food consumption (Fig. 1B), or in the 1-h 
consumption of palatable food (Fig. 1C).
Discussion and Conclusion
The absence of an orexigenic effect following icv infusion of RXFP3 agonists in 
mice suggests this RXFP3 action may not be strongly conserved across species. This 
apparent discrepancy was not predicted, as both species display an essentially iden-
tical regional distribution pattern of RXFP3 mRNA and protein (binding sites) (Ma 
et al., 2007; Smith et al., 2010). However, the precise cellular distribution of RXFP3 
within the hypothalamus and the relative downstream targets and signalling effects 
are currently unknown; and hence it is possible that RXFP3 activation directly or 
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indirectly influences feeding-related circuits within the hypothalamus in rats, but not 
mice. This conclusion is in line with observations that C57BL/6J relaxin-3 KO mice 
do not display any overt differences in feeding behaviour and body weight compared 
to WT controls, although due to the potential for compensation in these life-long 
knockout mice, examining the effects of acute pharmacological antagonism of RXFP3 
in WT mice remains an important future direction.
Neuronal circuits and transmitters that control behavioural arousal often also 
modulate feeding behaviour, as exemplified by orexin (Sakurai, 2007); an effect 
that is not surprising given that acquiring food is a major goal to ensure survival. 
Although at first the present data appear to suggest profound differences between 
rat and mouse relaxin-3 systems, anatomical and functional evidence suggests relax-
in-3/RXFP3 signalling primarily modulates behavioural arousal in both species. For 
example, relaxin-3 appears to be associated with an ascending arousal pathway in 
both rats (Ma et al., 2007) and mice (Smith et al., 2010, 2011). Furthermore, local infu-
sion of an RXFP3 agonist or antagonist into the septum of rats increases or decreas-
es hippocampal theta rhythm respectively, which is a process closely associated with 
and required for behavioural arousal (Ma et al., 2009); while in mice with voluntary 
access to running wheels, deletion of the relaxin-3 gene results in circadian hypoac-
tivity (Smith et al., 2012). Therefore, it seems likely that relaxin-3/RXFP3 signalling 
plays a similar broad role in promoting arousal in both species, although differences 
exist in how this manifests as specific behaviours. 
Figure 1. A: Equivalent amounts of regular chow consumed by satiated C57BL/6J mice in 1 h during the light 
phase following icv infusion of aCSF vehicle or 500 pmol of the RXFP3 agonists R3/I5 or H3 relaxin. B: Equivalent 
amounts of regular chow consumed by relaxin-3 knockout and wildtype littermate mice during an average 24 h 
period. C: Equivalent amounts of palatable food consumed by relaxin-3 knockout and wildtype littermates during 
a 1-h access period. Group sizes (n) are indicated within columns. Data are expressed as mean ± SEM.
55Pharmacological activation of RXFP3 is not orexigenic in C57BL/6J mice
Acknowledgments
This research was supported by National Health and Medical Research Council of 
Australia project grants 509246 (ALG) and 508995 (JDW), and by the Pratt and Besen 
Family Foundations (ALG) and the Victorian Government Operational Infrastructure 
Support Program.
References
Ganella D.E., Ryan P.J., Bathgate R.A.D., Gundlach A.L. (2012) Increased feeding and 
body weight gain in rats after acute and chronic activation of RXFP3 by relaxin-3 
and receptor-selective peptides: functional and therapeutic implications. Behav 
Pharmacol. 23: 516-525.
Liu C., Chen J., Kuei C., Sutton S., Nepomuceno D., Bonaventure P., Lovenberg T.W. 
(2005) Relaxin-3/insulin-like peptide 5 chimeric peptide, a selective ligand for G 
protein-coupled receptor (GPCR)135 and GPCR142 over leucine-rich repeat-con-
taining G protein-coupled receptor 7. Mol Pharmacol. 67: 231-240.
Ma S., Bonaventure P., Ferraro T., Shen P.J., Burazin T.C.D., Bathgate R.A.D., Liu C., 
Tregear G.W., Sutton S.W., Gundlach A.L. (2007) Relaxin-3 in GABA projection 
neurons of nucleus incertus suggests widespread influence on forebrain circuits 
via G-protein-coupled receptor-135 in the rat. Neuroscience. 144: 165-190.
Ma S., Olucha-Bordonau F.E., Hossain M.A., Lin F., Kuei C., Liu C., Wade J.D., Sut-
ton S.W., Nunez A., Gundlach A.L. (2009) Modulation of hippocampal theta oscil-
lations and spatial memory by relaxin-3 neurons of the nucleus incertus. Learn 
Mem. 16: 730-742.
McGowan B.M., Stanley S.A., Smith K.L., White N.E., Connolly M.M., Thompson 
E.L., Gardiner J.V., Murphy K.G., Ghatei M.A., Bloom S.R. (2005) Central relaxin-3 
administration causes hyperphagia in male Wistar rats. Endocrinology. 146: 3295-
3300.
Sakurai T. (2007) The neural circuit of orexin (hypocretin): maintaining sleep and 
wakefulness. Nat Rev Neurosci. 8: 171-181.
Shabanpoor F., Hossain M.A., Ryan P.J., Belgi A., Layfield S., Kocan M., Zhang S., 
Samuel C.S., Gundlach A.L., Bathgate R.A.D., Separovic F., Wade J.D. (2012) Min-
imization of human relaxin-3 leading to high-affinity analogues with increased 
selectivity for relaxin-family peptide 3 receptor (RXFP3) over RXFP1. J Med Chem. 
55: 1671-1681.
Smith C.M., Hosken I.T., Sutton S.W., Lawrence A.J., Gundlach A.L. (2012) Relax-
in-3 null mutation mice display a circadian hypoactivity phenotype. Genes Brain 
Behav. 11: 94-104.
Smith C.M., Ryan P.J., Hosken I.T., Ma S., Gundlach A.L. (2011) Relaxin-3 systems in 
the brain - The first 10 years. J Chem Neuroanat. 42: 262-275.
Smith C.M., Shen P.J., Banerjee A., Bonaventure P., Ma S., Bathgate R.A.D., Sutton S.W., 
Gundlach A.L. (2010) Distribution of relaxin-3 and RXFP3 within arousal, stress, affec-
tive, and cognitive circuits of mouse brain. J Comp Neurol. 518: 4016-4045.
